IN THE PRESS
FZ002 R&D IS PUBLISHED IN TOP JOURNAL
Research on FZata's leading drug candidate, FZ002, was published in Science Translational Medicine (2020 Oct 28;12(567)).
This break through study was reported by many journals, including Science magazine (https:///news/2020/10/antibody-producing-yeast-vanquishes-deadly-gut-infection-mice), Medical Press (https://medicalxpress.com/news/2020-10-yeast-common-bacterial-intestinal-infection.html), BiotechScope (https://biotechscope.com/antibody-secreting-yeast-immunotherapy-to-treat-deadly-gut-infection/) etc.
FZATA WINS NIH SBIR FAST-TRACK GRANT
FZata wins NIH SBIR Fast-track grant to support the development of FZ002.
FZATA IS SPOTLIGHTED BY EAGB
March 1, 2020
EAGB selected FZata as their Industry Spotlight: Life Science company.
FZATA, INC. WINS 3RD SBIR FUND
FZata is awarded an SBIR grant to support the development of a novel companion diagnostic assay for C. diff infection
FZATA WINS 2ND SBIR FUND
FZata receives an SBIR Phase I grant to support the development of a novel immunotherapy against comorbidity of C. diff infection and Inflammatory Bowel Disease
FZATA WINS NIH R01 GRANT
March 1, 2017
FZata is awarded an NIH R01 grant to support the development of a novel multi- specific antibody against C. diff infection.
FZATA IS HONORED "2017 MARYLAND INCUBATOR COMPANY OF THE YEAR: BEST LIFE SCIENCE COMPANY"
It's our great honor to be selected as the Maryland best life science incubator company!
FZATA, INC. WINS ITS FIRST SBIR GRANT
FZata is awarded a SBIR Phase I grant from NIAID to support the study of a novel oral immuo-therapy against C. diff infection.
As NIH grant awardee, FZata will strictly follow the NIH policy on Financial Conflict of Interest.